Fosamprenavir Expanded Access

ViiV Healthcare85 enrolled

Overview

This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.

Study Type

INTERVENTIONAL

Enrollment

Conditions

Infection, Human Immunodeficiency Virus

Interventions

fosamprenavirDRUG

Telzir®DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV-1 infected subjects. * Subjects must belong to one of the following populations: 1. Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs. 2. Subjects who already receive amprenavir (Agenerase®) 3. Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.

Locations (12)

GSK Investigational Site

Aarau, Switzerland

GSK Investigational Site

Basel, Switzerland

GSK Investigational Site

Bern, Switzerland

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.